Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{152148,
        author = {Pratibha Vannarwad and Akshata A. Lasure and Nandkishor B. Bavage and Shyamlila B. Bavage},
        title = {CHEMOTHERAPY FOR BREAST CANCER},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {8},
        number = {2},
        pages = {501-505},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=152148},
        abstract = {Breast cancer represents a major health problem, with more than a million new cases and 370,000 deaths worldwide yearly. Breast cancer remains the most prevalent form of cancer among women. The use of cytotoxic chemotherapy in both advanced and early stage breast carcinoma has made significant progress in the last 10 years with several landmark studies identifying clear survival benefits for newer therapies. Cytotoxic combination regimens developed in the 1970s were shown to produce higher response rates and longer durations of response and survival than single agent therapy. These regimens became the standard of care for the management of metastatic hormone- refectory breast cancer and more recently for primary breast carcinoma, randomized trials also have demonstrated that anthracycline containing combination were more effective than combination without anthracyclins.The improvement in the understanding of the molecular biological basis of breast cancer provides possible targets for novel therapies.this review will focus on the evidence j use of chemotherapy.},
        keywords = {Breast cancer, cytotoxic chemotherapy, metastatic breast carcinoma, anthracycline, chemotherapy.},
        month = {},
        }